Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $160.60 USD
Change Today +2.26 / 1.43%
Volume 1.0M
PRGO On Other Exchanges
New York
Tel Aviv
As of 8:04 PM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Treasury Building

Lower Grand Canal Street

Dublin, 2


Phone: 353 1 709 4000


products with approximately 7,400 SKUs. This segment has launched various new products, including a new ACO skin care line in the Nordic region, XLS (Medical) Max Strength in key markets, and a new dual action cough line in six new markets. This segment intends to roll out a Men's Health Vitamins line in the U.K. in partnership with Men's Health magazine, the Granufink urological product line beginning in the U.K. under the brand name Urostemol, and create a new self-care category in collaboration with the pharmacy chain Boots. As of June 27, 2015, this segment had approximately 50 strategic new product developments in 5 product categories. Customers, and Sales and Marketing The company’s customers include pharmacies, drug, and grocery stores located primarily in Europe, including Boots, ASDA (the U.K.), Tesco (the U.K.), DM, Rossmann, ETOS, and Kruidvat. This segment sells its products through an established pharmacy sales force and a network of pharmacists. Competition The company primarily competes with Reckitt Benckiser, Boehringer Ingelheim, Novartis International AG, and Johnson & Johnson. Rx Pharmaceuticals segment This segment develops, manufactures, and markets a portfolio of generic and specialty pharmaceutical prescription drugs primarily for the U.S. and the U.K. markets. This segment includes a range of topical dosage forms, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, and powders. The portfolio also includes select controlled substances, injectables, hormones, women's health products, oral solid dosage forms, and oral liquid formulations. The company’s development areas include other delivery systems, such as oral liquids, metered dose inhalers, injectables, and transdermal products, some of which the company is developing with third parties. The company’s other areas of expertise include its production capabilities for controlled substance and hormonal products. The company manufactures its topical, specialty, and oral products in the U.S., Israel, and the U.K.; and also source from various FDA-inspected third parties. In addition, this segment offers OTC products through the prescription channel (referred to as ‘ORx’, these products are marketed using the Perrigo name). ORx products are OTC products that are available for pharmacy fulfillment and healthcare reimbursement when prescribed by a physician. The company offers various ORx products that are reimbursable through various health plans and the U.S. Medicaid and Medicare programs. During 2015, the company acquired a portfolio of products from Lumara Health, Inc. (Lumara), a privately-held, Chesterfield, Missouri-based specialty pharmaceutical company. This acquisition further expanded the company’s women's healthcare product offerings. Lumara products are marketed and sold as branded products by a small specialty sales force. This segment markets approximately 800 generic prescription and ORx products with approximately 1,400 SKUs. The company holds the ANDA or product application for the drugs that it manufactures or enters into an arrangement with the application holder for the manufacture and/or marketing of certain products. As of June 27, 2015, the company, on its own or in collaboration with partners, had 10 Rx drug applications pending approval with the FDA. Customers, and Sales and Marketing The company’s customers include major wholesalers, including Cardinal Health, McKesson, and AmerisourceBergen; national and regional retail drug, supermarket and mass merchandise chains, including Walgreens, Walmart, CVS, Rite Aid, Kroger, and Safeway; hospitals; and pharmacies. ORx products are sold to the consumer through the pharmacy counter of primarily the same retail outlets as its OTC pharmaceutical and nutritional products. In addition, the company has a small specialty sales force consisting of representatives who visit healthcare professionals to educate them on the clinical characteristics and benefits of its branded products. Competition Among the company’s generic drug manufacturer competitors are Actavis plc; Apotex Corp.; Glenm


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRGO:US $160.60 USD +2.26

PRGO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Endo International PLC $64.27 USD +0.85
Mead Johnson Nutrition Co $72.03 USD -0.10
Mylan NV $42.55 USD -0.12
Sigma-Aldrich Corp $139.65 USD +0.04
Sun Pharmaceutical Industries Ltd 906.20 INR 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation PRGO Industry Range
Price/Earnings 100.0x
Price/Sales 5.0x
Price/Book 2.2x
Price/Cash Flow 181.1x
TEV/Sales 3.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PERRIGO CO PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at